Vaxcyte PCVX is a clinical-stage biotech focused on developing vaccines to prevent or treat bacterial infectious diseases. In ...

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccine-related adverse events.

(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today shared positive topline results ...

Childhood vaccinations have not recovered from the slump that happened after the pandemic, according to new research.

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays impact it. Click for my PCVX update.

Evercore ISI notes that Vaxcyte (PCVX) missed four serotypes versus Prevnar20 in the “all-important” infant data, adding that ...

Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...

PCV13 [pneumococcal 13-valent conjugate vaccine], or cohort 3: PPSV23 followed by or preceded by PCV13, PPSV23 preceded by PCV15 [pneumococcal 15-valent conjugate vaccine], or PCV15 alone).

These findings provide mechanistic evidence linking neonatal antibiotic exposure to impaired vaccine immunogenicity via ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

Meanwhile, the launch of new-generation innovative products, including the serum-free rabies vaccine, the 13-valent pneumococcal conjugate vaccine, the quadrivalent meningococcal conjugate vaccine, as ...